CRMD
NASDAQ · Pharmaceuticals
Cormedix Inc
$8.70
+0.10 (+1.16%)
Financial Highlights (FY 2026)
Revenue
302.06M
Net Income
158.01M
Gross Margin
88.5%
Profit Margin
52.3%
Rev Growth
+1,545.2%
D/E Ratio
0.36
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.5% | 36.0% | 36.0% | 36.0% |
| Operating Margin | 48.2% | 23.1% | 20.3% | 20.6% |
| Profit Margin | 52.3% | 16.5% | 16.5% | 20.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 302.06M | 151.82M | 142.81M | 140.45M |
| Gross Profit | 267.21M | 54.69M | 51.45M | 50.59M |
| Operating Income | 145.50M | 35.09M | 29.00M | 28.90M |
| Net Income | 158.01M | 25.07M | 23.58M | 28.46M |
| Gross Margin | 88.5% | 36.0% | 36.0% | 36.0% |
| Operating Margin | 48.2% | 23.1% | 20.3% | 20.6% |
| Profit Margin | 52.3% | 16.5% | 16.5% | 20.3% |
| Rev Growth | +1,545.2% | +9.9% | -6.7% | -6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 89.97M | 50.32M | 44.84M | 51.37M |
| Total Equity | 250.12M | 528.35M | 516.77M | 505.47M |
| D/E Ratio | 0.36 | 0.10 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 146.15M | 47.08M | 40.68M | 43.83M |
| Free Cash Flow | — | 14.58M | 22.25M | 13.22M |